NDAINJECTIONINJECTABLE
Approved
Jun 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CIS-PYRO (technetium tc99m pyrophosphate) by PharmaIN is radiopharmaceutical activity [moa]. First approved in 1987.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIS-PYRO is a radiopharmaceutical diagnostic agent containing Technetium TC99M bound to pyrophosphate, used for nuclear imaging procedures. It localizes in specific tissues based on radiopharmaceutical activity to visualize organ function and perfusion. The drug enables clinicians to detect cardiac, bone, and other tissue pathology through gamma camera imaging.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating defensive positioning and potential team consolidation.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CIS-PYRO offers stability in diagnostic imaging but limited growth upside given LOE approach; roles emphasize defending market share, managing payer relationships, and preparing for generic competition. Career advancement may require lateral moves to growth-stage products or specialty positioning in nuclear medicine.
Brand Manager
Worked on CIS-PYRO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.